Intelligence Profile
Clinical Applications
Alpha-lipoic acid has been investigated for several clinical applications, though the available evidence varies in quality and depth across different conditions.
Cancer-Related Applications
Cisplatin-Induced Ototoxicity Prevention: A completed Phase 2/3 clinical trial (NCT00477607) specifically examined alpha-lipoic acid's potential to prevent hearing loss in cancer patients receiving cisplatin chemotherapy. However, detailed results from this study are not provided in the available evidence.
Hepatoprotection: Recent research has explored alpha-lipoic acid's potential in mitigating cisplatin-induced liver damage. A 2026 study developed nanophytosomes co-loaded with glycyrrhetinic acid and alpha-lipoic acid as a strategy to protect against cisplatin-induced hepatocellular damage, though this represents early-stage pharmaceutical development rather than clinical application data.
Metabolic and Psychiatric Conditions
Antipsychotic-Induced Weight Gain: Alpha-lipoic acid has been studied as part of nutraceutical interventions for managing weight gain associated with antipsychotic medications in patients with schizophrenia spectrum disorders. A 2026 systematic review and meta-analysis examined the efficacy and tolerability of various nutraceuticals and phytotherapics for this indication, though specific results for alpha-lipoic acid are not detailed in the available evidence.
Cardiovascular and Metabolic Research
Heart Failure: Alpha-lipoic acid was investigated in a completed early-phase clinical trial (NCT03136029) examining exercise and nitric oxide pathways in heart failure with reduced ejection fraction, though specific outcomes are not provided.
Antioxidant Effects: Research has examined acute antioxidant supplementation effects, including racial and aging considerations (NCT02157207), though alpha-lipoic acid's specific role in this completed study is not detailed.
Reproductive Health
Ovarian Tissue Preservation: Alpha-lipoic acid has been studied as an antioxidant supplement in experimental models for ovarian tissue cryopreservation, according to a 2026 scoping review. This represents research-stage investigation rather than established clinical practice.
Safety Considerations
A 2026 narrative review addressed hypersensitivity reactions associated with nutraceuticals and dietary supplements, which may include alpha-lipoic acid, highlighting the importance of monitoring for adverse reactions.
Evidence Limitations
The available evidence provides limited specific clinical outcome data for alpha-lipoic acid across these applications. While multiple completed clinical trials are referenced, detailed efficacy and safety results are not provided in the current evidence base. Many applications remain in experimental or early clinical investigation phases.
This information is for educational purposes only and should not replace professional medical advice. Consult with a healthcare provider before starting any supplementation regimen.